Table 3 Cox regression analysis of DFS

Univariable analysis

 Tumor PLK4 IHC score

  >0 vs. ≤0

0.167

2.348 (0.700-7.882)

  >3 vs. ≤3

0.013

3.060 (1.266-7.395)

  >6 vs. ≤6

0.001

4.107 (1.843-9.153)

Age, ≥60 years vs. <60 years

0.084

2.086 (0.907-4.800)

Menopausal status, post-menopause vs. pre-menopause

0.169

2.340 (0.696-7.865)

Diabetes, yes vs. no

0.347

1.526 (0.632-3.683)

Hypertension, yes vs. no

0.205

1.688 (0.752-3.790)

Histological subtype

 Endometrioid carcinoma G1/G2 (reference)

1.000

 Endometrioid carcinoma G3 vs. endometrioid carcinoma G1/G2

0.003

5.415 (1.798-16.308)

 Serous endometrial carcinoma vs. endometrioid carcinoma G1/G2

0.004

4.708 (1.656-13.386)

 Clear cell endometrial carcinoma vs. endometrioid carcinoma G1/G2

0.002

6.714 (2.019-22.331)

Myometrial invasion ≥50%, yes vs. no

0.015

2.796 (1.223-6.393)

Cervical invasion, stromal vs. none or epithelia

0.001

3.741 (1.674-8.358)

Lymphovascular invasion, yes vs. no

0.031

2.427 (1.086-5.424)

Higher FIGO stage

0.002

1.729 (1.231-2.427)

CA125 abnormity, yes vs. no

0.178

1.740 (0.778-3.894)

CA19-9 abnormity, yes vs. no

0.315

1.533 (0.667-3.524)

CEA abnormity, yes vs. no

0.328

1.491 (0.670-3.322)

Adjuvant radiotherapy, yes vs. no

0.479

1.429 (0.531-3.843)

Adjuvant chemotherapy, yes vs. no

0.031

2.426 (1.086-5.424)

Multivariable analysis

 Tumor PLK4 IHC score, >6 vs. ≤6

0.008

3.156 (1.359-7.332)

Histological subtype

 Endometrioid carcinoma G1/G2 (reference)

1.000

 Endometrioid carcinoma G3 vs. endometrioid carcinoma G1/G2

0.001

7.617 (2.288-25.353)

 Serous endometrial carcinoma vs. endometrioid carcinoma G1/G2

0.002

5.393 (1.877-15.500)

 Clear cell endometrial carcinoma vs. endometrioid carcinoma G1/G2

0.003

6.339 (1.846-21.763)

Higher FIGO stage

<0.001

1.983 (1.361-2.889)